pBS-ACTB-C200-GFPfr1 Citations (2)

Originally described in: Evaluation of site-specific homologous recombination activity of BRCA1 by direct quantitation of gene editing efficiency.
Yoshino Y, Endo S, Chen Z, Qi H, Watanabe G, Chiba N Sci Rep. 2019 Feb 7;9(1):1644. doi: 10.1038/s41598-018-38311-x. PubMed Journal

---

Articles Citing pBS-ACTB-C200-GFPfr1

Articles
Paclitaxel sensitizes homologous recombination-proficient ovarian cancer cells to PARP inhibitor via the CDK1/BRCA1 pathway. Yanaihara N, Yoshino Y, Noguchi D, Tabata J, Takenaka M, Iida Y, Saito M, Yanagida S, Iwamoto M, Kiyokawa T, Chiba N, Okamoto A. Gynecol Oncol. 2023 Jan;168:83-91. doi: 10.1016/j.ygyno.2022.11.006. Epub 2022 Nov 17. PubMed
Bevacizumab increases the sensitivity of olaparib to homologous recombination-proficient ovarian cancer by suppressing CRY1 via PI3K/AKT pathway. Iida Y, Yanaihara N, Yoshino Y, Saito M, Saito R, Tabata J, Kawabata A, Takenaka M, Chiba N, Okamoto A. Front Oncol. 2024 Feb 14;14:1302850. doi: 10.3389/fonc.2024.1302850. eCollection 2024. PubMed

If you have published an article using this material, please email us at to have your article added to this page.